| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
MEGX is an active lidocaine metabolite that retains sodium channel-blocking activity and contributes to lidocaine analgesia; at the spinal level it promotes inhibitory neurotransmitter release, and its formation rate is rate-limited by hepatic CYP-mediated metabolism, making MEGX exposure a functional probe of CYP activity and hepatic clearance.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
MEGX-d6 is analytically inert as an isotope-labeled standard and does not carry independent pharmacological potency claims; its value lies in co-elution with unlabeled MEGX and stable ionization under ESI+, enabling accurate quantification of MEGX in biological matrices without isotopic interference in LC-MS/MS assays. |
| ln Vivo |
In vivo, MEGX formation from lidocaine is used as a real-time liver function test in clinical and preclinical settings, where the MEGX concentration at a defined time after lidocaine administration correlates with hepatic metabolic capacity; the d6 internal standard corrects for matrix effects and extraction recovery in these PK-based liver function assessments.
|
| Enzyme Assay |
Non-cell analytical binding and recovery experiments use protein precipitation with cold acetonitrile or liquid-liquid extraction, followed by centrifugation and evaporation; the reconstituted extract is injected onto a C18 reversed-phase column with formic acid-modified water/acetonitrile gradient, and MEGX-d6 is monitored by ESI+ MRM alongside unlabeled MEGX to establish calibration curves and recovery ratios.
|
| Cell Assay |
Cell-based hepatic metabolism experiments use primary human hepatocytes or CYP-expressing microsomes incubated with lidocaine; MEGX formation is quantified over time by LC-MS/MS with MEGX-d6 as internal standard, and intrinsic clearance (CLint) is calculated from the initial rate of MEGX appearance, enabling assessment of CYP inhibition or induction by co-incubated compounds.
|
| Animal Protocol |
In vivo liver function studies administer a standard lidocaine dose to rats, dogs, or human subjects and collect plasma at fixed intervals; MEGX is quantified by LC-MS/MS using MEGX-d6 as internal standard, and the MEGX concentration at 30 min (or the MEGX/lidocaine ratio) is used as an index of hepatic CYP activity and functional liver reserve, with PK parameters derived from the concentration–time profile.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of Monoethylglycinexylidide include glycyl dimethylamine and 3-hydroxyMonoethylglycinexylidide. Monoethylglycinexylidide is a known metabolite of lidocaine. |
| References | |
| Additional Infomation |
Monoethylglycinexylidide is an amino acid amide composed of 2,6-dimethylaniline and N-ethylglycine; it is the active metabolite of lidocaine, generated by oxidative deethylation. It can be used as a liver function indicator and is also a drug metabolite.
|
| Molecular Formula |
C12H18N2O
|
|---|---|
| Molecular Weight |
212.321093082428
|
| Exact Mass |
212.18
|
| CAS # |
1216698-89-3
|
| Related CAS # |
Monoethylglycinexylidide;7728-40-7
|
| PubChem CID |
24415
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.891
|
| tPSA |
44.62
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(NC1=C(C([2H])([2H])[2H])C=CC=C1C([2H])([2H])[2H])(=O)CNCC
|
| InChi Key |
WRMRXPASUROZGT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H18N2O/c1-4-13-8-11(15)14-12-9(2)6-5-7-10(12)3/h5-7,13H,4,8H2,1-3H3,(H,14,15)
|
| Chemical Name |
N-(2,6-dimethylphenyl)-2-(ethylamino)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7099 mL | 23.5494 mL | 47.0987 mL | |
| 5 mM | 0.9420 mL | 4.7099 mL | 9.4197 mL | |
| 10 mM | 0.4710 mL | 2.3549 mL | 4.7099 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.